Alisma orientale extract inhibits cell proliferation by promoting oxidative stress and apoptosis in prostate cancer cells

Prostate cancer is a prevalent malignancy in men, necessitating the development of more effective treatment drugs. Alisma is commonly used in clinical settings for various ailments, including tumors. However, its mechanism of action in prostate cancer cells remains unclear. This study aimed to clarify the effects of Alisma orientale extract (AOE) on prostate cancer. Our results showed that AOE inhibited prostate cancer cell growth and induced apoptosis while promoting oxidative stress. Mechanistically, AOE modulated the p38/nuclear factor kappa-B (NF-κB) pathway to inhibit prostate cancer progression. Taken together, these findings suggest that AOE could serve as a potential treatment for prostate cancer.

Prostate cancer; Alisma orientale extract (AOE); Apoptosis; Oxidative stress; p38/NF-κB pathway

[1] Gómez Rivas J, Fernandez L, Abad-Lopez P, Moreno-Sierra J. Androgen deprivation therapy in localized prostate cancer. Current status and future trends. Actas UrolóGicas EspañOlas. 2023; 47: 398–407.

[2] Tani M, Hayashi Y, Miki A, Wakita T, Horibe Y, Kakuta Y, et al. A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high-risk prostate cancer. IJU Case Reports. 2023; 6: 282–285.

[3] Wang Z, Zhang Y, Deng Q, Zhang J, Wang X, Liang H. Integrative analysis of androgen receptor interactors aberrations and associated prognostic significance in prostate cancer. Urology Journal. 2023; 20: 318–328.

[4] Talvitie AM, Ojala H, Tammela T, Pietilä I. Prostate cancer-related sexual dysfunction—the significance of social relations in men’s reconstructions of masculinity. To be published in Culture, Health & Sexuality. 2023. [Preprint].

[5] Ito Y, Tanaka N. Phylogeny of Alisma (Alismataceae) revisited: implications for polyploid evolution and species delimitation. Journal of Plant Research. 2023; 136: 613–629.

[6] Wei W, Li H, Deng Y, Zheng X, Zhou Y, Xue X. The combination of alisma and atractylodes ameliorates cerebral ischaemia/reperfusion injury by negatively regulating astrocyte-derived exosomal miR-200a-3p/141-3p by targeting SIRT1. Journal of Ethnopharmacology. 2023; 313: 116597.

[7] Feng Q, Yang Y, Qiao Y, Zheng Y, Yu X, Liu F, et al. Quercetin ameliorates diabetic kidney injury by inhibiting ferroptosis via activating Nrf2/HO-1 signaling pathway. The American Journal of Chinese Medicine. 2023; 51: 997–1018.

[8] Wu Y, Wang X, Yang L, Kang S, Yan G, Han Y, et al. Therapeutic effects of alisma orientale and its active constituents on cardiovascular disease and obesity. The American Journal of Chinese Medicine. 2023; 51: 623–650.

[9] Liu R, Sun Y, Di D, Zhang X, Zhu B, Wu H. PI3K/AKT/SERBP-1 pathway regulates alisma orientalis beverage treatment of atherosclerosis in APOE−/− high-fat diet mice. Pharmaceutical biology. 2023; 61: 473–487.

[10] Kwon MJ, Kim JN, Park J, Kim YT, Lee MJ, Kim BJ. Alisma canaliculatum extract affects AGS gastric cancer cells by inducing apoptosis. international Journal of Medical Sciences. 2021; 18: 2155–2161.

[11] Choi J, Ahn SS, Lim Y, Lee YH, Shin SY. Inhibitory effect of alisma canaliculatum ethanolic extract on NF-κB-dependent CXCR3 and CXCL10 expression in TNFα-exposed MDA-MB-231 breast cancer cells. International Journal of Molecular Sciences. 2018; 19: 2607.

[12] Yoshida I, Ito C, Matsuda S, Tsuji A, Yanaka N, Yuasa K. Alisol B, a triterpene from Alismatis rhizoma (dried rhizome of Alisma orientale), inhibits melanin production in murine B16 melanoma cells. Bioscience, Biotechnology, and Biochemistry. 2017; 81: 534–540.

[13] Zhao Y, Li ETS, Wang M. Alisol B 23-acetate induces autophagic-dependent apoptosis in human colon cancer cells via ROS generation and JNK activation. Oncotarget. 2017; 8: 70239–70249.

[14] Oka S, Sakaguchi K, Hayashida M, Ito S, Kurosawa K, Urakami S. First case report of robot-assisted radical cystectomy for bladder cancer that developed after salvage radiotherapy following radical prostatectomy for prostate cancer. IJU Case Reports. 2023; 6: 310–313.

[15] Hu B, Zhang H, Zhang Y, Jin Y. A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients. Cancer Imaging. 2023; 23: 82.

[16] Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, et al. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. European Journal of Gynaecological Oncology. 2023; 44: 17–25.

[17] Methods in Medicine CAM. Retracted: Alisol B 23-acetate increases the antitumor effect of bufalin on liver cancer through inactivating wnt/β-catenin axis. Computational and Mathematical Methods in Medicine. 2023; 2023: 9753946.

[18] Papachristodoulou A, Heidegger I, Virk RK, Di Bernardo M, Kim JY, Laplaca C, et al. Metformin overcomes the consequences of NKX3.1 loss to suppress prostate cancer progression. To be published in European Urology. 2023. [Preprint].

[19] Yao C, Li G, Cai M, Qian Y, Wang L, Xiao L, et al. Prostate cancer downregulated SIRP-alpha modulates apoptosis and proliferation through p38-MAPK/NF-kB/COX-2 signaling. Oncology Letters. 2017; 13: 4995–5001.

[20] Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kB, JNK, and ras signaling pathways. Oncogene. 2003; 22: 4314–4332.